Evidence map›Paper›PMID 40498096›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Inhibition of thioredoxin reductase 1 by evernic and vulpinic acids: a promising anticancer strategy on A549 cells.

Şükran Günaydın, Şeyda Nur Kalın, Emine Karaca Sulukoğlu, Ahmet Altay, Harun Budak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Şükran GünaydınScience Faculty, Department of Molecular Biology and Genetics, Atatürk University, 25240, Erzurum, Türkiye.ORCID 0000-0003-0971-7692
Şeyda Nur KalınScience Faculty, Department of Molecular Biology and Genetics, Atatürk University, 25240, Erzurum, Türkiye.ORCID 0000-0002-2594-2489
Emine Karaca SulukoğluScience Faculty, Department of Molecular Biology and Genetics, Atatürk University, 25240, Erzurum, Türkiye.ORCID 0000-0002-8991-5105
Ahmet Altay *Faculty of Science and Arts, Department of Chemistry, Erzincan Binali Yıldırım University, 24002, Erzincan, Türkiye. aaltay@erzincan.edu.tr.ORCID 0000-0001-8120-8900
Harun Budak *Science Faculty, Department of Molecular Biology and Genetics, Atatürk University, 25240, Erzurum, Türkiye. hbudak@atauni.edu.tr.ORCID 0000-0002-7371-8959

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TrxR1 (Thioredoxin reductase 1) is overexpressed in several types of cancer, containing lung cancer, which is closely linked to metastasis. Hence, TrxR1 has emerged as a target for cancer therapies. In this study, it was aimed to survey whether lecanoric (LA), evernic acid (EA), and vulpinic acid (VA) exert an anticancer effect on lung cancer (A549) cells by targeting the TrxR1 protein. The findings indicated that VA elicited a more notable cytotoxic activity in A549 cells (36.21 µg/mL) at a lower IC

Indexed as

Antineoplastic AgentsLung NeoplasmsThioredoxin Reductase 1A549 CellsApoptosisCell MovementCell SurvivalFuransHumansPhenylacetatesAntineoplastic AgentsFuransPhenylacetatesThioredoxin Reductase 1TXNRD1 protein, humanvulpinic acidAnticancer activityEvernic acidLung cancerThioredoxin reductase 1Vulpinic acid

Identifiers

PMID40498096
PMCPMC12678627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.